CG Oncology Inc. (CGON) shares tumbled 7.4% to $63.64 as of October 6, 2026, a significant decline from the prior close of $68.71. BestStocks flagged the session as a major change for CGON. The move is tied to price move down. Below, we break down what changed for CGON, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
CGON fell 7.4% to $63.64
CG Oncology Inc. (CGON) moved −7.99% from $69.17 to $63.64 on 2026-10-06. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The stock reached a new 30-day low on below-average volume (0.7x the 5-day average). Monitor the earnings release on 2026-11-13 for any guidance or clinical/operational updates that could clarify the recent weakness.
This summary describes the catalyst and move as first detected on Oct 6, 2026, 4:41 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsLow confidence
Rel. volume
0.8×
Below Avg
Vs peers
—
No comparable peers
Market cap
$5.6B
NASDAQ
Analyst target
$87
+35.9% vs price
Price chart
Sep 8 – Oct 6
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for CG Oncology Inc. investors
For CG Oncology Inc. investors, the recent signals add up to a bearish shift. On the constructive side: CG Oncology Inc. (CGON) moved +5.04% from $69.80 to $73.32 on 2026-07-09. Weighing against that: Material negative event; Sharp 7.4% decline — elevated risk. Wall Street's consensus price target sits at $86.50, implying +35.9% upside from $63.64. BestStocks rates the overall signal quality low (57/100). With earnings roughly 38 days out, the next report is the most likely near-term test of the move.
CGON price reaction
CGON last traded at $63.64, down $5.07 (-7.38%) from the previous close of $68.71. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $63.64 and $78.25, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on CG Oncology Inc. (CGON)
The consensus analyst price target on CG Oncology Inc. (CGON) is $86.50, 35.9% above the recent $63.64. Over the past 90 days analysts logged 0 upgrades, 3 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CGON line up.
▲ The bullish case
+Wall Street's consensus price target of $86.50 implies +35.9% upside from $63.64.
+The Street's most bullish target is $100.00 (+57.1%).
+CG Oncology Inc. (CGON) moved +5.04% from $69.80 to $73.32 on 2026-07-09.
▼ The bearish case
−Material negative event.
−Sharp 7.4% decline — elevated risk.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 6, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
CG Oncology Inc. (CGON) moved -2.84% from $69.35 to $67.38 on 2026-10-02. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.2x, indicating no unusual selling pressure.
Material / Earnings2026-10-01-3.6%
CG Oncology Inc. (CGON) moved -2.88% from $70.38 to $68.35 on 2026-10-01. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the move was not driven by unusual trading activity.
Material / Earnings2026-09-28+3.7%
CGON moved +3.97% from its $66.95 open to a $69.61 close on 2026-09-28.
CG Oncology Inc. moved -5.25% intraday from $73.36 to $69.51. CG Oncology Inc (CGON) stock is down 5.47% today [1.31], trading at $69.35 after closing the previous session at $73.36 [1.31].While there are no negative regulatory or clinical trial announcements directly impacting the company today [1.31], the downward movement is primarily driven by macro-valuation pressures and profit-taking. The stock has experienced a massive year-to-date run of roughly 73% to 76% , touching close to its 52-week high of $80.97 [1.31]. Market analysts recently pointed out that CGON appears fully priced and potentially overvalued on current market multiples. Because the market has already aggressively priced in the success of its bladder cancer pipeline (such as its cretostimogene program), short-term traders are capitalizing on recent gains, putting downward technical pressure on the stock. ## CG Oncology Inc (CGON) $69.34 -5.47% today As of Sep 24, 2:42 PM EDT • Disclaimer 10:00 AM 11:00 AM 12:00 PM 1:00 PM 2:00 PM 70 72 Prev close $73.36 Sep 24, 2026 9:35 AM - 2:42 PM 1D 5D 1M 6M YTD 1Y 5Y Max| Open 73.10 | Mkt cap $6.15B USD | 52-wk high 80.97 | | High 73.44 | P/E ratio- | 52-wk low 35.64 | | Low 68.15 | Div yield- | ### Core Factors Influencing the Downwa
Material / Earnings2026-09-23-5.6%
CGON moved -4.57% from its $76.87 open to a $73.36 close on 2026-09-23.
Material / Earnings2026-09-21+4.9%
CG Oncology Inc. (CGON) moved +2.72% from $76.17 to $78.25 on 2026-09-21. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Material / Earnings2026-09-02-1.7%
CG Oncology Inc. (CGON) moved -2.93% from $76.84 to $74.59 on 2026-09-02. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, indicating no unusual trading activity.
CG Oncology declined 6.10% to $74.19 intraday, driven by routine profit-taking and sector-wide volatility in clinical-stage oncology names following the company's Q2 earnings report in early August, which posted a wider-than-expected per-share loss. Volume of 266,619 shares traded 330 minutes into the session was 0.41x the historical average for that time—below typical levels—suggesting modest institutional participation in the pullback.
In-depth CGON event analyses
Permanent, dated analyses of CGON's most significant sessions.
CGON tumbled 7.4% to $63.64. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did CGON stock fall?
CGON lost 7.38% ($5.07) versus the prior close of $68.71, last trading at $63.64 on 0.8× average volume.
When is CG Oncology Inc.'s next earnings date?
CGON's next earnings report is estimated for 2026-11-13 — about 38 days away.
What is the analyst price target for CGON?
The consensus analyst price target for CGON is $86.50, about 35.9% above the current $63.64. Over the past 90 days, analysts recorded 0 upgrades, 3 maintains, and 0 downgrades.
How BestStocks tracks CGON
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for CGON, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 6, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
